Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system

Rheumatic Diseases Clinics of North America
Kyriakos A KirouMary K Crow

Abstract

After many years of anticipation, we have entered a period of promise for new lupus therapies; several clinical trials are planned or are in progress. The accelerated activity in systemic lupus erythematosus therapeutics has been driven by scientific advances. Enhanced understanding of the cells and mediators that drive autoimmunity and tissue damage has led to the identification of rational therapeutic targets. The conventional immunosuppressive therapies, including corticosteroids and cyclophosphamide, can be effective but at a high and unacceptable cost of adverse effects. There is high optimism that targeted therapies, including those that are specific for soluble mediators, will allow effective control of disease activity while sparing patients the damaging toxicities that are associated with traditional immunosuppressive agents.

References

Jul 5, 1979·The New England Journal of Medicine·J J HooksA L Notkins
Mar 1, 1992·Clinical Immunology and Immunopathology·L A HebertF G Cosio
Jan 28, 1988·Nature·C O Jacob, H O McDevitt
Feb 1, 1989·Arthritis and Rheumatism·C P Maury, A M Teppo
Aug 1, 1994·The Journal of Clinical Investigation·B K FinckD Wofsy
May 28, 1996·Proceedings of the National Academy of Sciences of the United States of America·R P Junghans, C L Anderson
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·Y WangL A Matis
Jun 2, 1998·Lupus·R Herrera-EsparzaE Avalos-Díaz
Jul 2, 1998·Clinical and Experimental Immunology·M MiharaY Ohsugi
Jan 23, 1999·The New England Journal of Medicine·Z Yu, V A Lennon
Feb 11, 1999·British Journal of Rheumatology·S LeeH Hashimoto
Jun 3, 2000·Annual Review of Immunology·V Ghetie, E S Ward
Aug 15, 2000·Seminars in Hematology·J B Bussel
Feb 24, 2001·Immunological Reviews·B Z Schmidt, H R Colten
Feb 27, 2003·Journal of Autoimmunity·Déborah BraunJocelyne Demengeot
Feb 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Emily C BaechlerTimothy W Behrens
Mar 19, 2003·The Journal of Experimental Medicine·Lynda BennettVirginia Pascual
Mar 19, 2003·The Journal of Experimental Medicine·Marie-Laure Santiago-RaberArgyrios N Theofilopoulos
Mar 26, 2003·Cytokine & Growth Factor Reviews·Timothy A Stewart
Jun 19, 2003·The Journal of Clinical Investigation·Hongbin SongStephen Tomlinson
Feb 6, 2004·The New England Journal of Medicine·Peter HillmenRussell P Rother
Feb 27, 2004·Autoimmunity·Mary K CrowJay Wohlgemuth
Feb 27, 2004·Autoimmunity·Carmen Gota, Leonard Calabrese
Mar 23, 2004·Annual Review of Immunology·Anthony P MandersonMark J Walport
Jul 3, 2004·Lupus·W Stohl

❮ Previous
Next ❯

Citations

Mar 28, 2008·Expert Review of Molecular Diagnostics·Chang-Hee Suh, Hyoun-Ah Kim
Feb 13, 2010·Expert Opinion on Emerging Drugs·Chi Chiu Mok
Oct 27, 2006·Expert Opinion on Emerging Drugs·Chi Chiu Mok
Apr 12, 2007·Expert Opinion on Pharmacotherapy·Marta MoscaStefano Bombardieri
Jun 1, 2014·Iranian Journal of Kidney Diseases·Pedram AhmadpoorMehrdad Rostami
Apr 23, 2010·Orvosi hetilap·Anna BazsóEmese Kiss

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Antibodies: Complement Activation

The complement system can be activated by antigen-associated antibody. In the classical pathway of complement activation, C1q, C4b, and C3b are all able to bind to the Fc portion of IgG or IgM. Find the latest research on antibodies and complement activation here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.